Clinical Trial Update: Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma

View source ↗

Summary

This update notes a targeted therapy trial for patients with EGFR-mutant lung adenocarcinoma and that enrollment is by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Lung Adenocarcinoma, EGFR Activating Mutation | Status: ENROLLING_BY_INVITATION